Trial document



drksid header

  DRKS00009815

Trial Description

start of 1:1-Block title

Title

Attentional processes and decision making in social interactions - Investigation of alterations in individuals with Borderline Personality Disorder and the relationship to different hormones

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

Social_Perception 2

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

People extremely differ in their perception of social situations, in their attentional focus, and in their ability to make decisions within social Encounters. Former research has shown that hormones may strongly influence our behaviour in social situations and our interactions with others. This (EEG-) study investigates the influence of oxytocin on the perception of and the reaction to facial expressions. Oxytocin is a hormone that plays a crucial role in attachment, social relationships, and the recognition of emotions in others.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

People extremely differ in how fast they react to visual stimuli in competitive situations. Former research has shown that different factors like the ability of our brain to regulate attentional and decision making processes and emotions. It has also been shown that hormones strongly influence our behaviour in social situations and our interactions with others. This (EEG-) study investigates the influence of oxytocin on the perception of and the reaction to facial expressions.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00009815
  •   2016/01/11
  •   [---]*
  •   yes
  •   Approved
  •   S-032/2015, Ethik-Kommission I der Medizinischen Fakultät Heidelberg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   F60.31 -  [generalization F60.3: Emotionally unstable personality disorder]
  •   Healthy Volunteers
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   BPD-Oxytocin condition: 25 female patients with BPD, one intranasal Administration of 24 I.U. oxytocin; after clinical diagnostic interviews (International Personality Disorder Examination; Loranger et al. 1994 and SCID-I) as well as several dimensional questionnaires for the assessment of clinical symptoms and personality traits (Borderline-Symptom-Liste; Bohus et al., 2007; Zanarini Scale; Zanarini et al. 2003; German Version of the Difficulty in Emotion Regulation Scale; Gratz et al., 2004; German version of the Childhood Trauma Questionnaire; Bernstein et al., 1998; German version of the State-Trait Anger Inventory; Spielberger, 1991; German Version of the State-Trait Anxiety Inventory; Laux et al., 1981; German version of the Barrat Impulsivity Scale; Patton et al., 1995; Dissociation; Freyberger, 1999; Multidimensional Mood Questionnaire; Steyer et al. 1997; Rejection Sensitivity; Bungert et al., in press; Screening Questionnaire for Hormone Assessments; Schultheiss & Stanton,
    2009; Life History of Aggression Inventory; Coccaro et al. 1997; Overt Aggression Sale Modified for Outpatients; OAS-M, Coccaro et al., 1991; Raven Matrices; Heller, 1981) one blood sample will be drawn for hormonal assessments. Participants will then be intranasally administered with 24 I.U. oxytocin or a placebo spray. In the following two Tasks, participants rate different facial expressions of a set of facial cues while an EEG is recorded.
  •   BPD-Placebo condition: 25 female patients with BPD, one intranasal Placebo Administration intranasal; see Arm 1 for procedure
  •   HC-Oxytocin condition: 25 female healthy volunteers; one intranasal Administration of 24 I.U. oxytocin; see Arm 1 for procedure
  •   HC-Placebo condition: 25 female healthy volunteers, one intranasal Placebo Administration intranasal; see Arm 1 for procedure
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   patient/subject, investigator/therapist
  •   Other
  •   Basic research/physiological study
  •   Other
  •   N/A
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Behavioral Data: Performance and reaction time; EEG: P1, N170, P300 for emotional faces after a single oxytocin vs. placebo administration in female BPD patients vs. healthy controls

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Exploratory correlations between behavioral and EEG data (see Primary outcome) and dimensional trait questionnaires (anger, German version of the State-Trait Anger Inventory; Spielberger, 1991; anxiety, German Version of the State-Trait Anxiety Inventory; depression, Beck Depression Inventory; aggressiveness, Life History of Aggression Inventory; Coccaro et al. 1997; Overt Aggression Sale Modified for Outpatients; OAS-M, Coccaro et al., 1991) after single oxytocin vs. Placebo Administration in female BPD patients vs. healthy volunteers.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2016/01/01
  •   100
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Female
  •   18   Years
  •   50   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

General inclusion criteria: age 18-50 years, readiness for participation. Additional inclusion criterion for patients with Borderline Personality Disorder: Borderline Personality Disorder assessed with the International Personality Disorder Examination.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

General exclusion criteria: actual pregnancy, lifetime diagnosis of any psychotic or bipolar disorders, substance dependence during the past year, a history of brain damage, severe internistic or neurological disease, claustrophobia. Additional exclusion criterion for healthy controls: more than one DSM-IV criterion for Borderline Personality Disorder fulfilled.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Deutsche Forschungsgemeinschaft
    • Kennedyallee 40
    • 53175  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2018/12/31
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.